An engineered virus kills cancer cells more effectively than another virus currently used in treatments, according to Hokkaido University researchers.
Hokkaido University researchers have engineered a virus that selectively targets and kills cancer cells. The virus, called dl355, has an even stronger anticancer effect than another engineered virus currently used in clinical practice, according to a study published in the journal Oncology Reports.
Molecular oncologist Fumihiro Higashino and colleagues deleted a gene involved in viral replication, called E4orf6, from a type of adenovirus. The team previously discovered that E4orf6 stabilizes a type of mRNA called ARE-mRNAs in the infected cells enabling viral replication. ARE-mRNAs are known to be stable in stressed cells and cancer cells, but rapidly degrade in normal cells.
In laboratory tests, they found that their modified adenovirus, called dl355, replicated and increased its number significantly more in cancer cells than it did in normal cells. Higashino explains “The E4orf6-lacking virus relies on the stable ARE-mRNAs in cancer cells for its replication.”
Some viruses can be used to treat cancers, as they replicate within the cells until they burst and die. The researchers infected several types of cultured cancer cells with 100 dl355 virus particles per cell and found that nearly all the cancer cells died within seven days. In contrast, most normal cells infected with the virus did not die, even after seven days. Several cancer cell lines managed to survive low doses of dl355, but all cancer cells were killed by the virus as the dose was increased. Tumour growth was also significantly suppressed when dl355 was administered to human tumour cells grown in mice.
Finally, the team compared the anticancer effects of dl355 with another anticancer adenovirus currently used in clinical practice, called dl1520. dl355 replication was higher in all cancer cell lines tested, including cervical and lung cancer cells, and was better at killing all but one type of cancer cell, compared to dl1520. Both viruses only killed very few normal cells.
The findings suggest that dl355 has potential to be an effective anticancer treatment, the team concludes. They suggest enhancing the stabilization of ARE-mRNAs in cancer cells could even further strengthen its effect, but Professor Higashino notes that further research is required. “While we think dl355 has the potential to be an effective treatment method in dealing with many types of cancers, much more research needs to be done. When we think of a timeline, at least five more years of further research may be required, possible more, on top of clinical trials,” Professor Higashino noted.
Learn more: Engineering a cancer-fighting virus
The Latest on: Engineered virus
via Google News
The Latest on: Engineered virus
- Recreating a Step in the Evolution of Viruseson July 6, 2021 at 6:05 am
An international team of researchers has shed new light on the way viruses evolved highly effective ways of spreading disease.
- Genetically-engineered pigs to be reared to fight diseaseon July 6, 2021 at 4:14 am
Pigs are to be genetically engineered in Edinburgh to be resistant to a respiratory disease. Porcine Reproductive and Respiratory Syndrome (PRRS). Researchers at Edinburgh University's Roslin ...
- World’s deadliest viruses were ‘shipped to Wuhan ‘leak lab’ from Canada by rogue scientists linked to Chinese military’on July 2, 2021 at 3:23 am
SOME of the world’s deadliest viruses were shipped to the Wuhan Institute of Virology from Canada by two rogue scientists with links to the Chinese military, it is reported. Bombshell ...
- Engineered T cells prevent translational shutdown in SARS-CoV-2 infected cellson July 1, 2021 at 7:50 pm
In a paper recently uploaded to the preprint server bioRxiv* by Schamel et al. (June 25th, 2021) engineered T cells against SARS-CoV-2 are tested against a range of cells in vitro, finding that the ...
- RGF ® Environmental Group PHI-CELL ® Technology Approved in Canada and United Kingdom to Inactivate Airborne Viruses in Indoor Environmentson June 30, 2021 at 9:00 pm
RGF® Environmental Group, Inc., a leading environmental design and manufacturing company, announces the approval of RGF’s patented PHI-CELL® technolog ...
- Engineered single-domain antibodies tackle COVID variantson June 30, 2021 at 10:04 am
Camels and llamas make antibodies that bind to targets using small, ‘nanobody’ protein domains. Mice have now been engineered to make nanobodies that might be more effective than conventional ...
- ‘Staying ahead of the virus’: AstraZeneca tests modified vaccine against variantson June 28, 2021 at 12:27 am
"Testing booster doses of existing vaccines and new variant vaccines is important to ensure we are best prepared to stay ahead of the coronavirus pandemic, should their use be needed." ...
- COVID-19 Virus Can't Survive in Pools, According to New Researchon June 27, 2021 at 5:00 am
Federal health officials have shared that there's little to no evidence that COVID-19 can spread among individuals in a pool setting. A new unpublished study out of Imperial College London suggests ...
- Engineered Nanobodies can Help Combat SARS-CoV-2 Virus and its Variantson June 24, 2021 at 7:43 am
Researchers are exploring a new strategy in the protracted fight against the infamous SARS-CoV-2 virus by designing nanobodies. These nanobodies are capable of neutralizing the virus variants in two ...
- COVID Lab-Leak Theory: ‘Rare’ Genetic Sequence Doesn’t Mean Virus Was Engineeredon June 24, 2021 at 5:29 am
Though CGG is less common than other codons, a WSJ article's argument fails to provide a reason that the sequence could not exist naturally.
via Bing News